12 Reasons Novavax Beats Pfizer For Titles Of Best Covid Vaccine And Best Covid Vaccine Stock

Summary

• The Novavax Covid vaccine has the highest efficacy against the original Covid-19 strain and the South Africa variant. It is also the only vaccine with proven efficacy against 3 variants.
• It is the only major Covid vaccine that can easily be made into a multivalent vaccine that contains multiple variants in a single dose.
• It also has the highest manufacturing capacity, the most geographically-diversified production and the highest quality group of partners.
• These and its many other advantages make it the top vaccine, will allow it to charge a premium, and will give it the largest share of the long-term market.
• While Pfizer has a very good vaccine and is a solid buy, Novavax is very undervalued with high upside, making it a strong buy.

Recently an article in BioSpace said: "Although largely off the radar for the general public ... analyst Josh Schimmer with Evercore ISI, believes that the Novavax (NASDAQ:NVAX) vaccine is the “vaccine to beat,” with it showing “strong potency and unique tolerability.” Analysts at B. Riley and JP Morgan also recently said the Novavax vaccine is best-in-class. However, the mainstream media (including most of the financial media) and the market have not paid attention to the analysts.

One of the primary things I look for while investing are instances in which the reality of a company is significantly different from what the media and the market thinks the reality of it is. The disparity between perception and reality is often an opportunity to either buy or short the stock. The media and the market failed to see the correct reality of Novavax for the past two years and thus missed out on its 4,000% gain.

Members of Seeking Alpha who read articles by me and other authors, however, have minted small fortunes by following our buy recommendations on the stock. An investment of $30,000 in early 2020 would be worth over $1 million now. After missing the boat, both the media and the market continue to make the same mistake about the company and its Covid vaccine.

The broad news media and the financial news media regularly portray Pfizer (NYSE:PFE)/BioNTech (BNTX) and Moderna (MRNA) as having the two best Covid vaccines. As this article will describe in detail, the reality is that Novavax’s vaccine is the best in at least 12 important ways. The market currently reflects this inaccurate perception by valuing Moderna ~400% higher than Novavax and BioNTech ~80% higher.

While the Pfizer/BioNTech and Moderna vaccines are similar overall, ultimately the Pfizer/BioNTech vaccine has a slight lead over Moderna's for three

Analyst’s Disclosure: I am/we are long PFE, NVAX, GSK, BNTX. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.